Autres langues G1 Therapeutics, Inc.

Actions

GTHX

US3621LQ1099

Temps réel estimé Cboe BZX Autres places de cotation 19:35:32 05/06/2024			Varia. 5j.	Varia. 1 janv.
3,15 ^USD	-1,25 %		-5,99 %	+2,95 %

28/05	G1 Therapeutics, Inc. annonce la présentation des résultats d'un essai clinique de phase 2 mature	CI
23/05	G1 Therapeutics annonce sa prochaine présentation au congrès 2024 de l'American Society of Clinical Oncology	CI

Autres langues

Débloquez toutes les actualités sur toutes les entreprises : Ne manquez plus une opportunité d'investissement rentable !

Inscription 100% Gratuite

G1 Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)	13:01
G1 THERAPEUTICS, INC. - MEANINGFUL IMPROVEMENT IN OVERALL SURVIVAL AND TOLERABILITY OBSERVED IN PATIENTS RECEIVING TRILACICLIB IN COMBINATION WITH A TROP2 ANTIBODY-DRUG CONJUGATE	29/05
Meaningful Improvement in Overall Survival (OS) and Tolerability Observed in Patients Receiving Trilaciclib in Combination with a TROP2 Antibody-Drug Conjugate (ADC)	28/05
G1 Therapeutics, Inc. Announces the Presentation of Mature Phase 2 Clinical Trial Results	28/05
G1 Therapeutics Announces Upcoming Presentation at the 2024 American Society of Clinical Oncology (ASCO) Meeting	23/05
G1 Therapeutics Announces Upcoming Presentation at the 2024 American Society of Clinical Oncology Meeting	23/05
G1 THERAPEUTICS TO PARTICIPATE IN TD COWEN'S 5TH ANNUAL ONCOLOGY INNOVATION SUMMIT	23/05
G1 THERAPEUTICS AND DEIMOS BIOSCIENCES ANNOUNCE GLOBAL LICENSE AGREEMENT FOR LEROCICLIB FOR RADIOPROTECTIVE USES	23/05
G1 Therapeutics to Participate in TD Cowen’s 5th Annual Oncology Innovation Summit	22/05
Sector Update: Health Care Stocks Lower Premarket Wednesday	22/05
G1 Therapeutics Grants Deimos Biosciences License to Market Anti-Radiation Treatment -- Shares Up Pre-Bell	22/05
G1 Therapeutics and Deimos Biosciences Announce Global (Excluding Asia-Pacific) License Agreement for Lerociclib for Radioprotective Uses	22/05
G1 Therapeutics and Deimos Biosciences Announce Global (Excluding Asia-Pacific) License Agreement for Lerociclib for Radioprotective Uses	22/05
Triple Negative Breast Cancer Pipeline, FDA Approvals, Unmet Needs, Preclinical and Discovery Stage Product, and Companies 2024 (Updated)	14/05
G1 Therapeutics : May 2024 Corporate Presentation	08/05
G1 Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)	01/05
Earnings Flash (GTHX) G1 THERAPEUTICS Reports Q1 Revenue $14.5M, vs. Street Est of $15.1M	01/05
G1 Therapeutics, Inc. Reaffirms Earnings Guidance for the Full Year 2024	01/05
G1 Therapeutics Provides First Quarter 2024 Financial Results and Operational Highlights	01/05
G1 Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	01/05

Aucun résultat pour cette recherche

Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Autres langues G1 Therapeutics, Inc.

Actions

GTHX

US3621LQ1099

Autres langues

Filtres